Intra-hepatic Chemotherapy With Oxaliplatin Every Second Week in Combination With Systemic Gemcitabine and Capecitabine in Combination With Cetuximab in Patient With Non-resectable Liver Metastases From Cholangiocarcinoma. A Phase II Trial.

Trial Profile

Intra-hepatic Chemotherapy With Oxaliplatin Every Second Week in Combination With Systemic Gemcitabine and Capecitabine in Combination With Cetuximab in Patient With Non-resectable Liver Metastases From Cholangiocarcinoma. A Phase II Trial.

Discontinued
Phase of Trial: Phase II

Latest Information Update: 16 Mar 2016

At a glance

  • Drugs Capecitabine (Primary) ; Cetuximab (Primary) ; Gemcitabine (Primary) ; Oxaliplatin (Primary)
  • Indications Cholangiocarcinoma; Liver metastases
  • Focus Biomarker; Therapeutic Use
  • Most Recent Events

    • 16 Mar 2016 Status changed from active, no longer recruiting to discontinued as reported by European Clinical Trials Database.
    • 14 Jun 2013 Planned end date changed from 1 Apr 2014 to 1 Mar 2015 as reported by ClinicalTrials.gov.
    • 31 May 2011 Status changed from not yet recruiting to recruiting as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top